Novasep to build world's largest chromatography plant for
18 October 2012
Novasep is to invest €30 million to build in Europe the
world's largest chromatography plant used for the production of a large
volume commercial API (active pharmaceutical ingredient).
The plant will be built on Novasep's existing Mourenx site in
France and will be operational and validated within 18 months. Both
the development of an advanced purification process and the plant
expansion within the challenging timescale are results of the sharp
increase in the projected demand for a large volume, highly purified
The €30 million investment follows two other significant global
investments in 2012. The first is the opening of a new 2,000sq m
facility in Shanghai, China and the second is a €3 million
investment to expand the Highly Potent API (HPAPI) manufacturing
capabilities at the facility in Le Mans, France.
Novasep has pioneered continuous chromatography for
pharmaceutical manufacturing for more than 20 years. Its SMB and
Varicol continuous chromatography technologies are currently used
for commercial scale production of several chiral APIs. The new
plant, designed by a Novasep in-house engineering team, will include
Varicol systems with 1,200 mm diameter columns operated at up to 70
bars, the largest ever built in the pharmaceutical industry.
The plant will enable the production of a highly purified API
from a complex mixture. The systems will also integrate
sophisticated solvent recovery systems for the recycling of 99.9% of
solvents, resulting in both a very cost-effective and
environmentally friendly process.
"Demand for Novasep's advanced, purification-based manufacturing
capabilities in the life science industries continues to increase as
drugs in development and reaching the market become more complex and
specific. This necessitates our third, and largest global plant
expansion in 2012," said Patrick Glaser, President and CEO of
"This successful project, the world's largest chromatography
plant in the pharmaceutical industry, demonstrates the validity of
the Novasep strategy which is based on the combination of synthesis,
biosynthesis and purification. We thank our institutional partners
for their active support and our shareholders for their strong
involvement to enable this transforming project."
Beyond Novasep's commitment, the €30 million investment has been
made possible through financial and/or logistic support by the
following partners: the association of local authorities of Lacq,
the General Council of Pyrénées Atlantiques, the Regional Council of
Aquitaine, the Economic Development Bureau, DIRECCTE Aquitaine, the
Prefecture of Pyrénées Atlantiques, the Total Group, and OSEO,
France's innovation partner. The plant will leverage the SOBEGI
platform's utility supply.